Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CANNAPHARMARX, INC.CPMD · Entity 8539 | Director · 10% owner | April 20, 2018 | June 19, 2020 |
| Vivakor, Inc.VIVK · Entity 8503 | Director · Chief Executive Officer · 10% owner | June 09, 2022 | June 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CANNAPHARMARX, INC.
Report date April 20, 2018 · Filed June 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A PreferredSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 16,000 |
Reported balance
After 2019-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-17 · Sale · Disposed 4,000 · Balance 16,000 F1: The conversion rights of the Series A Convertible Preferred Stock do not expire and can be exercised at any time. |
| Series A PreferredSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 26,000 |
Reported balance
After 2018-04-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-04-20 · Other · Disposed 10,000 · Balance 26,000 F2: The Reporting Person subscribed and paid for 30,000 Series A Convertible Preferred Shares directly from the Issuer. Subsequently, he verbally agreed to sell 10,000 of these shares, but the buyer failed to pay for the shares and the agreement was terminated. F1: The conversion rights of the Series A Convertible Preferred Stock do not expire and can be exercised at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: The conversion rights of the Series A Convertible Preferred Stock do not expire and can be exercised at any time.
F2: The Reporting Person subscribed and paid for 30,000 Series A Convertible Preferred Shares directly from the Issuer. Subsequently, he verbally agreed to sell 10,000 of these shares, but the buyer failed to pay for the shares and the agreement was terminated.
Vivakor, Inc.
Report date June 09, 2022 · Filed June 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option to Purchase Common StockSEC Table II · derivative / convertible security | Direct | 955,093 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 955,093 · Balance 955,093 F1: On June 9, 2022, Vivakor, Inc. (the "Company") entered into an Executive Employment Agreement (the "Agreement") with Matthew Nicosia. Pursuant to the Agreement, the Company granted Mr. Nicosia a stock option to acquire 955,053 shares of the Company's common stock (the "Stock Option"). The Stock Option will vest over two years with 278,356 of the shares vesting immediately, 225,579 of the shares vesting three (3) months after issuance, and the remaining 451,158 of the shares vesting in equal quarterly installments over the remaining seven (7) quarters (64,451 for 6 quarters and 64,642 in the last quarter), with an exercise price equal to 110% of the fair market value on the date grant, and which expires five (5) years after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 9, 2022, Vivakor, Inc. (the "Company") entered into an Executive Employment Agreement (the "Agreement") with Matthew Nicosia. Pursuant to the Agreement, the Company granted Mr. Nicosia a stock option to acquire 955,053 shares of the Company's common stock (the "Stock Option"). The Stock Option will vest over two years with 278,356 of the shares vesting immediately, 225,579 of the shares vesting three (3) months after issuance, and the remaining 451,158 of the shares vesting in equal quarterly installments over the remaining seven (7) quarters (64,451 for 6 quarters and 64,642 in the last quarter), with an exercise price equal to 110% of the fair market value on the date grant, and which expires five (5) years after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2022 Filed Jun 13, 2022 20:19 UTC | Vivakor, Inc. VIVK · Entity 8503 | GrantStock Option to Purchase Common Stock · Derivative | 955,093 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-22-004321 · ownership.xml · derivative · entry 1 Nicosia Matthew · CIK 0001452672 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955,093 Underlying: Common Stock · 955,093 shares Expires not disclosed F1 · derivative.exercise_price: On June 9, 2022, Vivakor, Inc. (the "Company") entered into an Executive Employment Agreement (the "Agreement") with Matthew Nicosia. Pursuant to the Agreement, the Company granted Mr. Nicosia a stock option to acquire 955,053 shares of the Company's common stock (the "Stock Option"). The Stock Option will vest over two years with 278,356 of the shares vesting immediately, 225,579 of the shares vesting three (3) months after issuance, and the remaining 451,158 of the shares vesting in equal quarterly installments over the remaining seven (7) quarters (64,451 for 6 quarters and 64,642 in the last quarter), with an exercise price equal to 110% of the fair market value on the date grant, and which expires five (5) years after the date of grant. F1 · derivative.exercise_date: On June 9, 2022, Vivakor, Inc. (the "Company") entered into an Executive Employment Agreement (the "Agreement") with Matthew Nicosia. Pursuant to the Agreement, the Company granted Mr. Nicosia a stock option to acquire 955,053 shares of the Company's common stock (the "Stock Option"). The Stock Option will vest over two years with 278,356 of the shares vesting immediately, 225,579 of the shares vesting three (3) months after issuance, and the remaining 451,158 of the shares vesting in equal quarterly installments over the remaining seven (7) quarters (64,451 for 6 quarters and 64,642 in the last quarter), with an exercise price equal to 110% of the fair market value on the date grant, and which expires five (5) years after the date of grant. F1 · derivative.expiration_date: On June 9, 2022, Vivakor, Inc. (the "Company") entered into an Executive Employment Agreement (the "Agreement") with Matthew Nicosia. Pursuant to the Agreement, the Company granted Mr. Nicosia a stock option to acquire 955,053 shares of the Company's common stock (the "Stock Option"). The Stock Option will vest over two years with 278,356 of the shares vesting immediately, 225,579 of the shares vesting three (3) months after issuance, and the remaining 451,158 of the shares vesting in equal quarterly installments over the remaining seven (7) quarters (64,451 for 6 quarters and 64,642 in the last quarter), with an exercise price equal to 110% of the fair market value on the date grant, and which expires five (5) years after the date of grant. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 10:43 UTC | Vivakor, Inc. VIVK · Entity 8503 | PurchaseCommon Stock | 3,528 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-22-001272 · ownership.xml · nonDerivative · entry 1 Nicosia Matthew · CIK 0001452672 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,191,228.51 F2 · price: Mr. Nicosia purchased 628 of the February 23, 2022 Purchased Shares at $2.50 per Common Stock, and the remaining 2,900 February 23, 2022 Purchased Shares at $2.65 per Common Stock. F1 · acquired: On February 23, 2022, Mr. Nicosia made a private purchase in the open market of 3528 shares of Common Stock, par value $0.001 per share ("Common Stock") (the "February 23, 2022 Purchased Shares"). F3 · balance_after: The total number of Common Stock beneficially owned by Mr. Nicosia includes (i) 4,189,428 Common Stock are held by AKMN Irrevocable Trust, of which Mr. Nicosia is a trustee; (ii) 262 Common Stock are held by Nicosia Family Trust, and (iii) 4438.51 Common Stock are held directly by Mr. Nicosia. F4 · ownership.direct: The February 23, 2022 Purchased Shares are held directly by Mr. Nicosia. Read SEC document |
| February 17, 2022 Filed Feb 24, 2022 20:00 UTC | Vivakor, Inc. VIVK · Entity 8503 | PurchaseCommon Stock | 320 | $2.95 | $944.00 |
DisclosureSEC source: 0001683168-22-001265 · ownership.xml · nonDerivative · entry 1 Nicosia Matthew · CIK 0001452672 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,190,600.51 F1 · acquired: On February 17, 2022, the Reporting Person made a private purchase in the open market of 320 shares of shares of Common Stock, par value $0.001 per share ("Common Stock") (the "February 17, 2022 Shares"). F3 · balance_after: The total number of Common Stock beneficially owned by Mr. Nicosia, includes (i) 4,189,428 Common Stock held by AKMN Irrevocable Trust, of which Mr. Nicosia is a trustee; (ii) 262 Common Stock held by Nicosia Family Trust, and (iii) 910.51 Common Stock are owned directly by Mr. Nicosia. F2 · ownership.direct: The February 17, 2022 Shares are owned directly by Mr. Nicosia. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 15:37 UTC | Vivakor, Inc. VIVK · Entity 8503 | PurchaseCommon Stock | 320 | $2.95 | $944.00 |
DisclosureSEC source: 0001683168-22-001152 · ownership.xml · nonDerivative · entry 1 Nicosia Matthew · CIK 0001452672 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,190,010 F1 · acquired: On February 16, 2022, the Reporting Person made a private purchase in the open market of 320 shares of shares of Common Stock, par value $0.001 per share. F2 · ownership.nature: The shares of common stock ("Common Stock") beneficially owned by Matthew Nicosia includes 4,189,428 Common Stock held by AKMN Irrevocable Trust and 262 Common Stock held by Nicosia Family Trust. Matthew Nicosia is the trustee of the AKMN Irrevocable Trust. Read SEC document |
| February 16, 2022 Filed Feb 24, 2022 20:01 UTC Amendment | Vivakor, Inc. VIVK · Entity 8503 | PurchaseCommon Stock | 590.51 | $3.05 | $1,801.06 |
DisclosureSEC source: 0001683168-22-001266 · ownership.xml · nonDerivative · entry 1 Nicosia Matthew · CIK 0001452672 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,190,280.51 F1 · acquired: On February 16, 2022, the Reporting Person made a private purchase in the open market of 590.51 shares of Common Stock, par value $0.001 per share ("Common Stock"). F2 · balance_after: The total number of Common Stock beneficially owned by Mr. Nicosia, includes (i) 4,189,428 Common Stock held by AKMN Irrevocable Trust, of which Mr. Nicosia is a trustee; (ii) 262 Common Stock held by Nicosia Family Trust, and (iii) 590.51 Common Stock are owned directly by Mr. Nicosia. F2 · ownership.nature: The total number of Common Stock beneficially owned by Mr. Nicosia, includes (i) 4,189,428 Common Stock held by AKMN Irrevocable Trust, of which Mr. Nicosia is a trustee; (ii) 262 Common Stock held by Nicosia Family Trust, and (iii) 590.51 Common Stock are owned directly by Mr. Nicosia. Read SEC document |
| June 17, 2019 Filed Jun 19, 2020 15:22 UTC | CANNAPHARMARX, INC. CPMD · Entity 8539 | SaleSeries A Preferred · Derivative | 4,000 | $1.00 Strike: $0.00 | $4,000.00 |
DisclosureSEC source: 0001683168-20-002002 · ownership.xml · derivative · entry 1 Nicosia Matthew · CIK 0001452672 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 5,000,000 shares Expires not disclosed F1 · derivative.expiration_date: The conversion rights of the Series A Convertible Preferred Stock do not expire and can be exercised at any time. Read SEC document |
| April 20, 2018 Filed Jun 19, 2020 15:22 UTC | CANNAPHARMARX, INC. CPMD · Entity 8539 | OtherSeries A Preferred · Derivative | 10,000 | $1.00 Strike: $0.00 | $10,000.00 |
DisclosureSEC source: 0001683168-20-002002 · ownership.xml · derivative · entry 2 Nicosia Matthew · CIK 0001452672 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 12,500,000 shares Expires not disclosed F2 · kind: The Reporting Person subscribed and paid for 30,000 Series A Convertible Preferred Shares directly from the Issuer. Subsequently, he verbally agreed to sell 10,000 of these shares, but the buyer failed to pay for the shares and the agreement was terminated. F1 · derivative.expiration_date: The conversion rights of the Series A Convertible Preferred Stock do not expire and can be exercised at any time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.